Impact of prophylactic pyridoxine on occurrence of hand–foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer

Yoshimoto, Nobuyasu; Yamashita, Toshinari; Fujita, Takashi; Hayashi, Hironori; Tsunoda, Nobuyuki; Kimura, M.; Tsuzuki, Norimasa; Yamashita, Hiroko; Toyama, Tatsuya; Kondo, Naoto; Iwata, Hiroji

doi:10.1007/s12282-009-0171-3

Cited by 29 publications

(47 citation statements)

References 23 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antolin and colleagues recently reported the results of a phase II neoadjuvant study from patients who received dose-dense docetaxel (100 mg/m 2 ) followed by ddAC (60/600 mg/m 2 ). The incidence of ≥grade 3 skin toxicity was reportedly 13.1 % during docetaxel [35]. A phase II study by Puhalla and colleagues demonstrated that the administration of docetaxel (75 mg/m 2 ) after AC (60/600 mg/m 2 ) in a dose-dense schedule resulted in higher incidence of HFS than the reverse sequence (29 vs 4 % grade 2/3 HFS, respectively) [33].…”

Section: Discussionmentioning

confidence: 99%

Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review

Poi

Berger

Lustberg

et al. 2013

Support Care Cancer

View full text Add to dashboard Cite

Purpose As the result of a recent national shortage in paclitaxel, some patients who were receiving or scheduled to receive weekly paclitaxel were converted to every 3-week (q3w) docetaxel with granulocyte colony-stimulating factor support. Our institution noted higher than expected incidence of severe skin toxicity events attributable to docetaxel during the shortage period among our breast cancer patients. In this report, we summarize the clinical course of the first five cases, review the literature surrounding docetaxel-induced skin toxicity, and offer possible prevention and treatment strategies to improve docetaxel tolerability. Methods The observation period for this case series was August 1 through October 21, 2011. All patients treated with docetaxel were identified from our electronic medical record. Operable stage I–III breast cancer patients who received ≥1 dose of docetaxel monotherapy at 75–100 mg/m2 q3w were included in this study. The cases of grade 3–4 docetaxel-induced skin toxicities identified by the treating oncologists were then contacted and signed an informed consent through an Institutional Review Board-approved protocol. Results Thirty-four patients met the inclusion criteria. Five patients (14.7 %) experienced grade 3 skin toxicity events attributable to docetaxel, a significantly higher rate than previously reported for docetaxel dosed at 75–100 mg/m2. Conclusions Docetaxel-induced dermatologic toxicity is well characterized; nonetheless, its etiology is largely unknown and evidence-based prevention and management strategies are lacking. This report shows that the use of docetaxel 75–100 mg/m2 q3w subsequent to dose-dense doxorubicin and cyclophosphamide regimen can lead to unacceptable rate of severe skin toxicity.

show abstract

Section: Discussionmentioning

confidence: 99%

Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review

Poi

Berger

Lustberg

et al. 2013

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…For patients with metastatic triple-negative breast cancer, cisplatin + gemcitabine regimen might be an alternative or even the favorable first-line chemotherapy strategy when compared with the more established paclitaxel + gemcitabine regimen [42]. For women with metastatic breast cancer, doxorubicin and paclitaxel as first-line therapy has an obvious advantage over FAC in the aspects of response rate, median time to progression, as well as in overall survival [43]. In elderly metastatic breast cancer patients, the first-line single-agent chemotherapy of both pegylated liposomal doxorubicin and capecitabine showed comparable efficacy and acceptable tolerance [17].…”

Section: Discussionmentioning

confidence: 99%

A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer

et al. 2016

View full text Add to dashboard Cite

ObjectiveTo compare the incidence of toxicity of 8 different chemotherapy regimens, including doxorubicin + paclitaxel, doxorubicin, capecitabine, CMF (cyclophosphamide + methotrexate + 5-fluorouracil), FAC (fluorouracil + doxorubicin + cyclophosphamide), doxorubicin + docetaxel, doxorubicin + cyclophosphamide and paclitaxel in the treatment of metastatic/advanced breast cancer.ResultsThis network meta-analysis included 8 randomized controlled trials (RCTs). The findings revealed that, with regard to capecitabine alone regimen exhibited higher incidence of nausea/vomiting than doxorubicin + paclitaxel regimen, doxorubicin alone regimen and paclitaxel alone regimen in the treatment of patients with metastatic/advanced breast cancer (OR = 32.48, 95% CI = 1.65~2340.57; OR = 22.75, 95% CI = 1.03~1923.52; OR = 59.63, 95% CI = 2.22~5664.88, respectively). Furthermore, doxorubicin + cyclophosphamide regimen had lower incidence of febrile neutropenia than doxorubicin + docetaxel (OR = 0.17, 95% CI = 0.03~0.96). No significant difference in the incidence of stomatitis was observed among eight chemotherapy regimens.Materials and MethodsWe initially searched PubMed, Cochrane Library and Embase databases from the founding of these databases to January 2016. Eligible studies investigating the 8 different chemotherapy regimens for treatment of metastatic/advanced breast cancer were included for direct and indirect comparison. The odds ratio (OR) and surface under the cumulative ranking curves (SUCRA) value of the incidence of toxicity among eight chemotherapy regimens were analyzed.ConclusionsCapecitabine alone regimen and doxorubicin + docetaxel regimen may have a more frequent toxicity in the treatment of metastatic/advanced breast cancer.

show abstract

“…Further investigation of such a relationship in patients with MBC is required before conclusions can be drawn. Meanwhile, suggestions that this effect may be explained by localization of thymidine phosphorylase in the palms [19] or a high thymidine phosphorylase:dihydropyrimidine dehydrogenase ratio require validation [20] .…”

Section: Discussionmentioning

confidence: 99%

Study of Low-Dose Capecitabine Monotherapy for Metastatic Breast Cancer

et al. 2010

View full text Add to dashboard Cite

Background: Capecitabine is an established therapy for metastatic breast cancer. In Japan, a 4 weekly regimen is often used, but data for this schedule in the first-line setting are lacking. Methods: Metastatic breast cancer patients who had received no chemotherapy for recurrent disease received capecitabine 825 mg/m² twice daily, on days 1–21 of a 28-day cycle until disease progression or unacceptable toxicity. The primary endpoint was response rate. Results: In 33 eligible patients, median age was 53 years (range 27–73). Prior adjuvant therapy included an anthracycline in 90% and a taxane in 40%. The response rate was 18%; a further 24% had stable disease for ≧6 months. Median progression-free and overall survival were 6.9 and 24.8 months, respectively. The only grade 3 events were neutropenia (6%) and hand-foot syndrome (15%). Conclusions: These preliminary results confirm previous data showing that a lower capecitabine dose is an active and well-tolerated first-line therapy for metastatic breast cancer.

show abstract

Impact of prophylactic pyridoxine on occurrence of hand–foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer

Abstract: Prophylactic pyridoxine and urea ointment at first appearance of symptoms appears to reduce the risk of severe capecitabine-induced HFS. However, randomized data are required to determine the true effect of these measures.

Cited by 29 publications

References 23 publications

Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review

Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review

A network meta-analysis for toxicity of eight chemotherapy regimens in the treatment of metastatic/advanced breast cancer

Study of Low-Dose Capecitabine Monotherapy for Metastatic Breast Cancer

Contact Info

Product

Resources

About